The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Metals ions and neurodegeneration
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Protein folding and misfolding
Dobson, C. M. (2003) · Nature · doi:10.1038/nature02261 · Cited by 4,791
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Reactive Oxygen Species and the Central Nervous System
Halliwell, B. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10990.x · Cited by 2,947
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Research works printed but not linked: 98
- Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain of Parkinson’s but not incidental Lewy body disease. J Neurochem 69:1326–1329 · DOI · Paper page
- Allan SM, Rothwell NJ (2003) Inflammation in central nervous system injury. Phil Trans R Soc Lond B Biol Sci 358:1669–1677 · DOI · Paper page
- Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol 5:629–640 · DOI · Paper page
- Antzutkin ON, Leapman RD, Balbach JJ, Tycko R (2002) Sopramolecular structural constraints on Alzheimer’s β-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochemistry 41:15436–15450 · DOI · Paper page
- Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, Martins RN (2003) Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res Rev 43:1–16 · DOI · Paper page
- Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteosome system by protein aggregation. Science 292:1552–1555 · DOI · Paper page
- Bonilla E (2000) Huntington disease. A review. J Clin Invest 41:117–141
- Brion S, Mirol J, Psimaras A (1973) Recent findings in Pick’s disease. In: Zimmerman HM (eds) Progress in neuropathology, vol 2. Grune and Stratton, New York, pp 421–452
- Brown DR (2001) Copper and prion disease. Br Res Bull 55:165–173 · DOI · Paper page
- Brunk UT, Jones CB, Sohal RS (1992) A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. Mut Res 275:395–403 · DOI · Paper page
- Bush AI, Huang X, Fairlie DP (1999) The possible origin of free radicals from amyloid β-peptides in Alzheimer’s disease. Neurobiol Ageing 20:335–337 · DOI
- Butterfield DA, Kanski J (2001). Brain oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 122:945–962 · DOI · Paper page
- Cherny RA, Barnham KJ, Lynch T et al (2000). Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer’s disease. J Struct Biol 130:209–216 · DOI
- Chetley A, Gilbert D (1986) Health action international. International Organisation of Consumers Unions, The Hangue
- Claesen ME, Clements ML (1989) Ridding the world of hydroxyquinolines. Br Med J 299:527–528 · DOI
- Cohen AS, Shirahama T, Skinner M (1982) Electron microscopy of amyloid. In: Harris JR (eds) Electron microscopy of proteins, vol 3. Academic Press, London UK, pp 165–205
- Cohen FE (1999) Protein misfolding and prion diseases. J Mol Biol 293:313–320 · DOI
- Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 271:20291–20299 · DOI · Paper page
- Crapper Mclachlan DR, Dalton AJ, Kruck TPA et al (1991) Effect of desferrioxamine on the clinical progress of Alzheimer’s disease. Lancet 337:1304–1308 · DOI · Paper page
- Crossthwaite AJ, Williams RJ (2002) Hydrogen peroxide-mediated phosphorilation of ERK1/2, Akt/PKB and JNK in cortical neurons: dependence on Ca2+ and PI 3-kinase. J Neurochem 80:24–36 · DOI · Paper page
- Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16:285–298 · DOI · Paper page
- Di Patti MC, Persichini T, Mazzone V, Polticelli F, Colasanti M, Musci G (2004) Interleukin-1 beta up-regulates iron efflux in rat C6 glioma cells through modulation of ceruloplasmin and ferroportin-1 synthesis. Neurosci Lett 363:182–186 · DOI
- Dobson MC (2003a) Protein folding and disease: a view from the first horizon symposium. Nat Drug Disc 2:154–160 · DOI
- Duffy PE, Tennyson VM (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and Locus caeruleus in Parkinson’s disease. J Neuropathol Exp Neurol 24:398–414 · DOI · Paper page
- Floyd RA (1999) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 222:236–245 · DOI · Paper page
- Floyd RA, Hensley K (2002) Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 23:795–807 · DOI · Paper page
- Gotz ME, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress: Free radical production in neural degeneration. Pharmacol Ther 63:37–122 · DOI · Paper page
- Grunblatt E, Mandel S, Youdim MB (2000) MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies. J Neurol 247(Suppl 2):95–102 · DOI
- Habgood MD, Liu ZD, Dehkordi LS, Khodr HH, Abbott J, Hider RC (1999) Investigation into the correlation between the structure of hydroxypyridinones and blood–brain barrier permeability. Biochem Pharmacol 57:1305–1310 · DOI
- Harris DC, Aisen P (1973) Facilitation of Fe(II) autoxidation by Fe(III) complexing agents. Biochim Biophys Acta 329:156–158 · DOI · Paper page
- Hartley DM, Walsh DM, Ye CP et al (1999) Protofibrillar intermediates of amyloid b-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurones. J Neurosci 19(20):8876–8884 · DOI · Paper page
- Hedge ML, Jagannatha Rao KS (2003) Challenges and complexities of α-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson’s disease. Arch Biochem Biophys 418:169–178 · DOI
- Hider RC, Hall AD (1991) Clinically useful chelators of tripositive elements. Prog Med Chem 28:41–173 · DOI
- Hider RC (1995) Potential protection from toxicity by oral iron chelators. Toxicol Lett 82–83:961–967 · DOI
- Hijazi N, Shaked Y, Rosenmann H, Ben-Hur T, Gabizon R (2003) Copper binding to PrPC may inhibit prion disease propagation. Br Res 993:192–200 · DOI
- Hirsh EC, Brandel J-P, Galle P (1991) Iron and aluminium increase in the substantia nigra of patients with Parkinson’s disease: an X-ray microanalysis. J Neurochem 56:446–451 · DOI · Paper page
- Holander D, Ricketts D, Boyd CAR (1988) Importance of probe molecular geometry in determining intestinal permeability. Can J Gastroenterol 2:35A–38A
- Hsiao K, Chapman P, Nilsen S et al (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99–102 · DOI · Paper page
- Huang X, Atwood CS, Hartshorn MA et al (1999) The Aβ peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38:7609–7616 · DOI · Paper page
- Jeffrey M, Goodsir CM, Bruce ME, Mcbride PA, Scott JR (1994) Infection-specific prion protein (PrP) accumulates on neuronal plasmalemma in scrapie-infected mice. Ann NY Acad Sci 724:327–330 · DOI
- Jelliger KA (1999) The role of iron in neurodegeneration: prospects for pharmacology of Parkinson’s disease. Drugs Aging 14:115–140 · DOI · Paper page
- Kaur D, Yantiri F, Rajagopalan S et al (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37:899–909 · DOI · Paper page
- Laine J, Marc M-E, Sy M-S, Axelrad H (2001) Cellular and subcellular morphological localization of normal prion protein in rodent cerebellum. Eur J Neurosci 14:47–56 · DOI
- Lan J, Jiang DH (1997) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104:469–481 · DOI · Paper page
- Lee J-Y, Friedman JE, Angel I, Kozak A, Kohj JY (2004) The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β-amyloid precursor protein transgenic mice. Neurobiol aging 25:1315–1321 · DOI · Paper page
- Levine SM, Chakrabarty A (2004) The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann NY Acad Sci 1012:252–266 · DOI · Paper page
- Liu ZD, Lockwood M, Rose S, Theobald AE, Hider RC (2001) Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase. Biochem Pharmacol 61:285–290 · DOI
- Liu ZD, Hider RC (2002a) Design of clinically useful iron(III)-selective chelators. Med Res Rev 22:26–64 · DOI · Paper page
- Liu ZD, Kayyali R, Hider RC, Porter JB, Theobald AE (2002) Design, synthesis, and evaluation of novel 2-substitued 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators. J Med Chem 45:631–639 · DOI
- Lozoff B, Beard J, Connor J, Barbara F, Georgieff M, Schallert T (2006) Long-lasting neural and behavioural effects of iron deficiency in infancy. Nutr Rev 64:S34–43 · DOI · Paper page
- Lue LF, Kuo Y-M, Roher AE et al (1999) Soluble amyloid β-peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155:853–862 · DOI · Paper page
- Maguire-Zeiss KA, Short DW, Federoff HJ (2005) Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson’s disease? Brain Res Mol Brain 134(1):18–23 · DOI
- Mandel S, Weinreb O, Amit T, Youdim MB (2005) Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 48:379–387 · DOI · Paper page
- Martell AE, Smith RM (1974–1989) Critical stability constant, vol 1–6. Plenum Press, London
- Maxton DG, Bjarnason I, Reynolds AP, Catt SD, Peters TJ, Menzies IS (1986). Lactulose, 51Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability. Clin Sci 71:71–80 · DOI · Paper page
- Mc Lean CA, Cherny RA, Fraser FW et al (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860–866 · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
- Merz PA, Sommerville RA, Wisniewsky HM, Ikbal K (1981). Abnormal fibrils from scrapie-infected brain. Acta Neuropathol 54:63–74 (Berlin) · DOI · Paper page
- Mizuno Y, Ohta S, Tanaka M et al (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun 163:1450–1455 · DOI · Paper page
- Molina-Holgado F, Williams RJ, Gaeta A et al (2006) Neuroprotective actions of an iron chelator against Alzheimer’s disease-relevant insults. Poster session, 10th international conference on Alzheimer’s disease and related disorders’s, Madrid, Spain
- Oakley GP (1973) The neurotoxicity of the halogenated hydroxyquinolines. JAMA 225(4):395–397 · doi:10.1001/jama.1973.03220310031006
- O’Brien-Ladner AR, Nelson SR, Murphy WJ, Blumer BM, Wesselius LJ (2000) Iron is a regulatory component of human IL-1beta production. Support for regional variability in the lung. Am J Respir Cell Mol Biol 23:112–119 · DOI
- Olanow CW (1992) Magnetic resonance imaging in parkinsonism. Neurol Clin North Am 405–420 · DOI
- Olanow CW, Youdim MB (1996) Neurodegeneration and neuroprotection in Parkinson’s disease. Academic Press, pp 55–59 · DOI
- Olivieri N, Koren G, Hermann C et al (1990) Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 336:1275–1279 · DOI · Paper page
- Paik SR, Shin H-J, Lee J-H, Chang C-S, Kim J (1999) Copper(II)-induced self-oligomerisation of α-synuclein. Biochem J 340:821–828 · doi:10.1042/bj3400821 · Paper page
- Palm A (1932) Untersuchung in des chinolin reihe. Arch Exp Pathol Pharmacol 199:176–185 · DOI
- Pan K, Baldwin M, Nguyen J et al (1993) Conversion of α-helices β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 90:10962–10966 · DOI · Paper page
- Prusiner SB, Mckinley MP, Bowman KA et al (1983) Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35:349–358 · DOI · Paper page
- Prusiner SB (1991) Molecular biology of prion disease. Science 252:1515–1522 · DOI · Paper page
- Prusiner SB (2001) Neurodegenerative diseases and prions. N Engl J Med 344:1516–1526 · DOI · Paper page
- Riederer P, Sofic E, Rausch WD, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 52:515–520 · DOI · Paper page
- Rochet JC, Lansbury PT (2000) Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 10:60–80 · DOI · Paper page
- Roher AE, Chaney MO, Kuo Y-M et al (1996) Morphology and toxicity of Aβ-(1–12) dimmer derived from neuritic and vascular amyloid deposits of Alzheimer’s disease. J Biol Chem 271:20631–20635 · DOI · Paper page
- Rogers JT, Lahiri DK (2004) Metal and inflammatory targets for Alzheimer’s disease. Curr Drug Targets 5:535–551 · DOI
- Rose FC, Gawel M (1984) Clioquinol neurotoxicity: an overview. Acta Neurol Scand 80(Suppl 100):137–145
- Saggu H, Cooksey J, Dexter D (1989) A selective increase in a particular superoxide dismutase activity in Parkinsonian substantia nigra. J Neurochem 53:692–697 · DOI · Paper page
- Sanchez-Ramos J, Overvick E, Ames BN (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2’-deoxy-guanoxine) is increased in nigro-striatum of Parkinson’s disease brain. Neurodegeneration 3:197–204
- Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000) Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross β-conformation. Proc Natl Acad Sci USA 97:4897–4902 · DOI · Paper page
- Shastry BS (2003) Neurodegenerative disorders of protein aggregation. Neurochem Int 43:1–7 · DOI · Paper page
- Sherki YG, Melamed E, Offen D (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40:959–975 · DOI · Paper page
- Shin R-W, Kruck TPA, Murayama H, Kitamoto T (2003) A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated τ of Alzheimer’s disease. Br Res 961:139–146 · DOI
- Sikorski P, Atkins EDT, Serpell LC (2003) Structure and texture of fibrous crystals formed by Alzheimer’s Aβ (11–15) peptide fragment. Structure 11:915–926 · DOI
- Sofic E, Riederer P, Heinsen H (1988) Increased Iron(Iii) and total iron content in post mortem, substantia nigra of parkinsonian brain. J Neural Trans 74:199–205 · DOI · Paper page
- Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 142:128–130 · DOI · Paper page
- Stahl N, Borchelt DR, Hsiao K, Prusiner SB (1987) Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 51:229–240 · DOI · Paper page
- Terry RD, Masliah E, Salmon DP et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580 · DOI · Paper page
- Torok M, Milton S, Kayed R et al (2002) Structural and dynamic features of Alzheimer’s Aβ peptide in amyloid fibrils studied by site-directed spin labelling. J Biol Chem 277:40810–40815 · DOI · Paper page
- Tsubaki T, Honma Y, Hosh M (1971) Neurological syndrome associated with clioquinol. Lancet 1:696–697 · DOI
- Tycko R (2004) Progress towards a molecular-level structural understanding of amyloid fibrils. Curr Opin Struct Biol 14:1–8 · DOI · Paper page
- Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB (1993) Characterisation of amyloid peptide from human cerebrospinal fluid. J Neurochem 61:1965–1968 · DOI · Paper page
- Wang SS, Becerra-Arteaga A, Good TA (2002) Development of a novel diffusion-based method to estimate the size of the aggregated Aβ species responsible for neurotoxicity. Biotechnol Bioeng 80:50–59 · DOI
- Wisniewsky HM, Coblentz JM, Terry RD (1972) Pick’s disease. A clinical and ultrastructural study. Arch Neurol 26:97–108 · DOI
- Xu J, Kao S-Y, Lee FJS, Song W, Jin L-W, Yankner BA (2002) Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600–606 · DOI · Paper page
- Ye FQ, Allen PS, Martin WRW (1996) Basal ganglia iron content in Parkinson’s disease measured with magnetic resonance. Mov Disord 11:243–249 · DOI
- Yokel RA, Fredenburg AM, Meurer KA, Skinner TL (1995) Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators. Drug Metab Dispos 23:1178–1180
- Youdim MB, Grunblatt E, Mandel S (1999) The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson’s disease with iron chelators. Ann NY Acad Sci 890:7–25 · DOI
- Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson’s disease. FEBS Lett 510:216–220 · DOI · Paper page
- Zhang X, Haaf M, Todorich B et al (2005) Cytokine toxicity to oligodendrocyte precursors is mediated by iron. Glia 52(3):199–208 · DOI
Cited by
Copper in diseases and treatments, and copper‐based anticancer strategies
Tisato, F., Marzano, C., Porchia, M., Pellei, M., & Santini, C. (2010) · Medicinal Research Reviews · doi:10.1002/med.20174 · Cited by 797
Bioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 672
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Metals, oxidative stress and neurodegeneration: A focus on iron, manganese and mercury
Farina, M., Avila, D. S., da Rocha, J. B. T., & Aschner, M. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.006 · Cited by 553
Battin, E. E., & Brumaghim, J. L. (2009) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-009-9054-7 · Cited by 476
Metadata
- Authors
- Molina-Holgado, F., Hider, R. C., Gaeta, A., Williams, R., & Francis, P.
- Venue
- BioMetals
- Published
- 2007-02-09
- Volume
- 20
- Issue
- 3-4
- Pages
- 639-654
- ISSN
- 0966-0844 (ISSN-L)
- 1572-8773
- OpenAlex
- W2068609215
- Cited by
- 207
- References
- 26
- FWCI
- 12.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metals ions and neurodegeneration. https://app.cochat.ai/papers/10.1007/s10534-006-9033-z
- The paper
- Molina-Holgado, F., Hider, R. C., Gaeta, A., Williams, R., & Francis, P. (2007). Metals ions and neurodegeneration. BioMetals. https://doi.org/10.1007/s10534-006-9033-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.